You are here

Pfizer Announces FDA Acceptance for Review of Application to Expand Labeling for XELJANZ® (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis to Include Inhibition of Progression of Structural Damage

Pfizer Announces FDA Acceptance for Review of Application to Expand Labeling for XELJANZ® (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis to Include Inhibition of Progression of Structural Damage

Submitted by admin on June 22, 2013 - 9:44am

Source:

Yahoo/BusinessWire

News Tags:

rheumatoid arthritis

Headline:

Pfizer Announces FDA Acceptance for Review of Application to Expand Labeling for XELJANZ® (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis to Include Inhibition of Progression of Structural Damage